Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Total Revenue
1,491,212
1,313,646
1,116,854
889,895
Cost of Revenue
315,264
241,786
209,620
152,008
Gross Profit
1,175,948
1,071,860
907,234
737,887
Operating Expenses
Research Development
696,328
610,753
661,905
634,806
Selling General and Administrative
604,353
554,336
476,593
402,271
Non Recurring
--
--
--
--
Others
48,791
46,471
572,165
(188,488)
Total Operating Expenses
1,349,472
1,211,560
1,710,663
848,589
Operating Income or Loss
(173,524)
(139,700)
(803,429)
(110,702)
Income from Continuing Operations
Total Other Income/Expenses Net
51,652
131,679
4,391
(38,773)
Earnings Before Interest And Taxes
(99,041)
3,107
(791,551)
(144,974)
Interest Expense
43,664
38,982
39,499
9,750
Income Before Tax
(142,705)
(35,875)
(831,050)
(154,724)
Income Tax Expense
(65,494)
81,167
(200,840)
17,075
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(77,211)
(117,042)
(630,210)
(171,799)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(77,211)
(117,042)
(630,210)
(171,799)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(77,211)
(117,042)
(630,210)
(171,799)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information